Glucose-induced serum- and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression

被引:22
作者
Khan, ZA
Barbin, YP
Farhangkhoee, H
Beier, N
Scholz, W
Chakrabarti, S [1 ]
机构
[1] Univ Western Ontario, Dept Pathol, London, ON, Canada
[2] Merck KgaA, Biomed Res, Diabet & Complicat, Darmstadt, Germany
[3] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada
[4] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Res Program, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Surg, Boston, MA 02115 USA
基金
加拿大健康研究院;
关键词
serum- and glucocorticoid-regulated kinase; oncofetal fibronectin; extracellular matrix; ET-1; TGF-beta; 1;
D O I
10.1016/j.bbrc.2005.01.135
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Preferential expression of oncofetal extra domain-B fibronectin (EDB+ FN), a proposed angiogenic marker, has been shown in proliferative diabetic retinopathy. High levels of glucose also increase EDB+ FN expression in endothelial cells (ECs) via transforming growth factor-beta1 (TGF-beta1) and endothelin-1 (ET-1). The present study was aimed at elucidating the role of serum- and glucocorticoid-regulated kinase (SGK-1) in glucose-induced EDB+ FN expression. Using human macro- and microvascular ECs, we show that high levels of glucose, TGF-beta1, and ET-1 increase the EDB+ FN expression via SGK-1 alteration at the mRNA, protein, and activity levels. Inhibition of TGF-beta1 and ET-1 prevented glucose-induced SGK-1 activation and the EDB+ FN expression. Furthermore, using siRNA-mediated SGK-1 gene silencing, we show that glucose-induced EDB+ FN expression can be completely prevented. These findings provide first evidence of glucose-induced SGK-1 activation in altered EDB+ FN expression and provide novel avenues for therapeutic modalities. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 23 条
[1]  
Aleksandrovski YA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1249
[2]   THE FIBRONECTIN ISOFORM CONTAINING THE ED-B ONCOFETAL DOMAIN - A MARKER OF ANGIOGENESIS [J].
CASTELLANI, P ;
VIALE, G ;
DORCARATTO, A ;
NICOLO, G ;
KACZMAREK, J ;
QUERZE, G ;
ZARDI, L .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (05) :612-618
[3]   Differential activation of NF-κB and AP-1 in increased fibronectin synthesis in target organs of diabetic complications [J].
Chen, SL ;
Khan, ZA ;
Cukiernik, M ;
Chakrabarti, S .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (06) :E1089-E1097
[4]   High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-κB and AP-1 [J].
Chen, SL ;
Mukherjee, S ;
Chakraborty, C ;
Chakrabarti, S .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2003, 284 (02) :C263-C272
[5]   Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats [J].
Evans, T ;
Deng, DX ;
Chen, SL ;
Chakrabarti, S .
DIABETES, 2000, 49 (04) :662-666
[6]   Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity [J].
Firestone, GL ;
Giampaolo, JR ;
O'Keeffe, BA .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2003, 13 (01) :1-12
[7]  
Hay E.D., 1991, CELL BIOL EXTRACELLU, V2nd, DOI DOI 10.1007/978-1-4615-3770-0
[8]  
Khan ZA, 2004, DIABETES, V53, pA443
[9]   Oncofetal fibronectin in diabetic retinopathy [J].
Khan, ZA ;
Cukiernik, M ;
Gonder, JR ;
Chakrabarti, S .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (01) :287-295
[10]   Endothelins in chronic diabetic complications [J].
Khan, ZA ;
Chakrabarti, S .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2003, 81 (06) :622-634